5-Fluorouracil, a drug mainly used in the treatment of gastrointestinal tract neoplasms, was administered i.p. to BALB/c mice at the dose of 30 mg/kg body weight once a week for 50 weeks to test its carcinogenicity. The treatment induced a significant increase in lung tumor in both sexes (males, p < 0.05; females, p < 0.01) and tumors of the lymphoreticular system in female mice (p < 0.001). These results suggest that 5-fluorouracil is carcinogenic in mice.
DraganiT.A.: Analysis of tumor incidence in BALB/c mice used as controls in carcinogenicity experiments.Tumori, 65: 665–675, 1979.
4.
GoodmanL.S., GilmanA.: The Pharmacological Basis of Therapeutics.5th Edn., pp. 1364–1369, MacMillan, New York, 1975.
5.
HadidianZ., FredricksonT.N., WeisburgerE.K., WeisburgerJ.H., GlassR.M., MantelN.: Tests for chemical carcinogens. Report on the activity of derivatives of aromatic amines, nitrosamines, quinolines, nitroalkanes, amides, epoxides, azi-ridines and purine antimetabolites.J. Natl. Cancer Inst., 41: 985–1036, 1968.
6.
HarrisonS.D.Jr., DenineE.P., PeckhamJ.C.: Qualitative and quantitative toxicity of single and sequential sublethal doses of 5-fluorouracil in BDF1 mice.Cancer Treat. Rep., 62: 533–545, 1978.
7.
HillB.H.R.: Occurrence of squamous carcinoma in hyperkeratosis and bowenoid lesions treated with 5-fluorouracil.Aust. J. Dermatol., 11: 107, 1970.
8.
HomburgerF., TregerA., BogerE.: Inhibition of murine subcutaneous and intravenous benza(rst)pentaphene carcinogenesis by sweet orange oils and d-limonene.Oncology, 25: 1–10, 1971.
9.
International Agency for Research on Cancer.IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans.Some Antineoplastic and Immunosuppressive Agents. Vol. 26, pp. 217–235, IARC, Lyon, France, 1981.
KleinE., MilgromH., StollH.L., HelmF., WalkerH.J., HoltermannO.A.: Topical 5-fluorouracil chemotherapy for premalignant and malignant epidermal neoplasms. In: « Cancer Chemotherapy II », BrodskyI., and KahnS.B. (eds.), pp. 147–166, Grune and Stratton Inc., New York, 1972.
13.
KurtisB., RosenT.: Squamous-cell carcinoma arising in a basal-cell epithelioma treated with 5-fluorouracil.J. Dermatol. Surg. Oncol., 5: 394–396, 1979.
14.
MaierP., SchmidW.: Ten model mutagens evaluated by the micronucleus test.Mutat. Res., 40: 325–338, 1976.
15.
MillerE.: The metabolism and pharmacology of 5-fluorouracil.J. Surg. Oncol., 3: 309–315, 1971.
16.
MoustacchiE., MarcovichH.: Induction of « petite » colony mutations in yeast by 5-fluorouracil (Fr). C.R.Acad. Sci., Paris, 256: 5646–5648, 1963.
17.
PattengaleP.K., TaylorC.R.: Experimental models of lym-phoproliferative disease. The mouse as a model for human non-Hodgkin's lymphomas and related leukemias.Am. J. Pathol., 113: 237–265, 1983.
18.
PetoR., PikeM.C., ArmitageP., BreslowN.E., CoxD.R., HowardS.V., MantelN., McPhersonK., PetoJ., SmithP.G.: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples.Br. J. Cancer, 35: 1–39, 1977.
19.
PetoR., PikeM.C., DayN.E., GrayR.G., LeeP.N., ParishS., PetoJ., RichardsS., WahrendorfJ.: Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. In: « IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans », Suppl .2, Long-term and Short-term Screening Assays for Carcinogens: A Critical Appraisal, pp. 311–426, IARC, Lyon, France, 1980.
20.
RegelsonW., BrossI.D., HananianJ., NigogoyganG.: Incidence of second primary tumors in children with cancer and leukemia: a seven-year survey of 150 consecutive autopsied cases.Cancer, 18: 58–72, 1965.
21.
ReimerR.R., HooverR., FraumeniJ.F.Jr., YoungR.C.: Acute leukemia after alkylating-agent therapy of ovarian cancer.New Engl. J. Med., 297: 177–181, 1977.
22.
SchmählD., OsswaldH.: Experimentelle Untersuchungen über carcinogene Wirkungen von Krebs-chemotherapeutica und immunosuppressiva. Arzneimittel-Forsch.(Drug Res.), 20: 1461–1467, 1970.
23.
SeinoY., NagaoM., YahagiT., HoshiA., KawachiT., SugimuraT.: Mutagenicity of several classes of antitumor agents to « Salmonella typhimurium » TA98, TA100 and TA92.Cancer Res., 38: 2148–2156, 1978.
24.
WadeH.: Martindale, The Extra Pharmacopoeia, 27th Edn., The Pharmaceutical Press, pp. 148–150, London, 1977.
